Appili Therapeutics Provides Enrollment Update for Its Phase 3 PRESECO Trial Evaluating the Oral Antiviral Favipiravir as an Early Treatment in COVID-19

Appili Therapeutics Provides Enrollment Update for Its Phase 3 PRESECO Trial Evaluating the Oral Antiviral Favipiravir as an Early Treatment in COVID-19

Appili Therapeutics Inc. (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases,

today announced that its Phase 3 PRESECO (PReventing SEvere COvid-19) clinical trial is actively recruiting participants in 12 out of 20 sites in the United States.

Based on current forecasts,
Appili believes that

it will reach the enrollment threshold required to provide an interim data readout by late March 2021.

PRESECO：

is evaluating favipiravir, an oral antiviral, in the early treatment of COVID-19 in the outpatient setting.

In addition, the Company is pursuing regulatory approvals to expand PRESECO into sites in Mexico, Brazil, and Colombia.

Along with generic producer Dr. Reddy’s, the company’s favipiravir-based product for treating early onset COVID-19

was quietly submitted as well to Health Canada for Market Authorization, as reported by TrialSite on Dec. 22.

https://trialsitenews.com/appili-therapeutics-provides-enrollment-update-for-its-phase-3-preseco-trial-evaluating-the-oral-antiviral-favipiravir-as-an-early-treatment-in-covid-19/